Invest-NL and Invest International invest €17.5M in Forbion fund to support innovative biotech companies

|

|

Last update:

Amsterdam-based Invest-NL, a national financing and development institution, announced on Friday that it has invested €7.5M in the Forbion BioEconomy Fund I.

Forbion BioEconomy Fund I is a newly launched investment strategy of Forbion, a life sciences venture capital firm.

The fund focuses on investing in innovative biotech companies that develop sustainable solutions across four sectors: Food, Agriculture, Materials, and Environment Technologies. 

Forbian focuses primarily on companies that have already been further developed and have demonstrated that their products work. 

The fund will actively support these biotech companies during their next growth phase in the Netherlands and Europe. 

The announcement comes a few weeks after raising over €2B across its two newest funds — Forbion Growth Opportunities III and Forbion Ventures VII, bringing assets under management at Forbion to €5B.

“The Forbion BioEconomy fund is one of the few funds active in the Netherlands in the field of biotechnology, a sector with a strong need for additional knowledge and capital. The fund specifically focuses on the transition in materials and food production, which fits seamlessly with our mission to realise a circular economy and a climate-neutral food system,” says David de Vries, Investment Analyst at Invest-NL.   

In addition to Invest-NL, Invest International is also joining the Forbion BioEconomy fund with an investment of €10M.

Based out of The Hague, Invest International is an impact investor that offers financial support to Dutch businesses and partner governments in other countries.

A couple of days back, Invest International invested a €10M senior loan in Amsterdam-based Organic Development Finance (ODF) to support SMEs in emerging markets.

Forbion: Global life sciences venture capital firm 

Based out of Naarden, the Netherlands, Forbion invests in innovative biotech companies, managing approximately €5B across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.

The VC invests in companies that are creating new biotechnology products, like alternative proteins and biobased materials.

Forbion typically selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives.

Topics:

Follow us:

Vigneshwar Ravichandran

Vigneshwar has been a News Reporter at Silicon Canals since 2018. A seasoned technology journalist with almost a decade of experience, he covers the European startup ecosystem, from AI and Web3 to clean energy and health tech. Previously, he was a content producer and consumer product reviewer for leading Indian digital media, including NDTV, GizBot, and FoneArena. He graduated with a Bachelor's degree in Electronics and Instrumentation in Chennai and a Diploma in Broadcasting Journalism in New Delhi.

Partner eventsMore events

Current Month

12dec4:00 pm9:30 pmAI in ActionPractical Insights for Digital Transformation

28jan4:00 pm10:00 pmUnlocking operational efficiency with AIInsights for your future

Share to...